{"prompt": "['5U19MH109988-02', 'Implementation Research Protocol', 'Scaling Up Science-based Mental Health Interventions in Latin America', 'Version 15.4', 'April 14, 2021', 'plans for both major and minor deviations as appropriate. Those corrective action plans may be', \"reviewed/approved by the lead investigators with overall approval by the site's IRB. All protocol\", 'deviations will be monitored at each site for (1) significance, (2) frequency, and (3) impact on the study', 'objectives, to ensure that site performance does not compromise the integrity of the trial.', \"Additionally, each site is responsible for reviewing their local IRB's definition of a protocol deviation or\", 'violation and understanding which events need to be reported. Sites must recognize that the IRB', 'definition of a reportable event may differ and act accordingly in following all reporting requirements', 'for both entities.', '15.16 Safety Monitoring', \"Principal Investigators' Roles and Responsibilities for Data and Safety Monitoring. The Principal\", 'Investigators will assume primary responsibility for overseeing all data and safety monitoring functions', 'to ensure the safety of participants in the research proposed within this application and to ensure the', 'validity and integrity of the data obtained in these studies. The Principal Investigators will also regularly', 'meet with the Co-Investigators and Consultants to track study progress and review these monitoring', 'procedures. The investigative team will regularly oversee all aspects of the study, including participant', 'recruitment, Informed Consent, data collection, data management and data analysis procedures, as well', 'as regularly assess the risk/benefit ratio associated with participation in the study.', 'The investigative team will meet regularly (scheduled meetings once weekly) for the entire duration of', 'the project.', 'Data and Safety Monitoring Board (DSMB)', 'An independent NIMH Data and Safety Monitoring Board (DSMB) will examine accumulating data to', \"assure protection of participants' safety and data integrity throughout the duration of the study. The\", 'DSMB conducts established biannual reviews of accumulating safety and efficacy data (an additional', 'reviews as indicated). It will determine whether there is support for continuation of the trial, or evidence', 'that study procedures should be changed, or if the trial should be halted, for reasons relating to the safety', 'of the study participants, the efficacy of the treatment under study, or inadequate trial performance (e.g.,', 'poor recruitment) or concerns about data integrity.', 'The study data will be reviewed by the NIMH Data and Safety Monitoring Board (DSMB) biannually.', 'The DSMB will receive a data report from the study team on a schedule determined by the DSMB. The', \"study team's submission to the DSMB is expected to follow the established reporting format developed\", 'in consultation with NIMH collaborator(s). The report will include the major variables necessary for', 'monitoring safety and quality of data collection and integrity of the study, including subject enrollment', 'and retention. The DSMB will also review the study protocol and consents before the onset of the study,', 'and will review amendments to these documents. Based on this review, the DSMB has the authority to', 'prevent the study to start or to stop the study after it has started.', 'The Principal Investigators will ensure all required DSMB reports are prepared, as required (as well as', 'all required reporting to IRBs).', 'Adverse Events (AEs)', '55']['5U19MH109988-02', 'Implementation Research Protocol', 'Scaling Up Science-based Mental Health Interventions in Latin America', 'Version 15.4', 'April 14, 2021', 'The Principal Investigators may appoint a Study Clinician (MD, PhD, or PI) for this study, who will', 'review or provide consultation for each Adverse Event (AE) as needed. These reviews will include an', 'assessment of whether the event was serious (Serious Adverse Event (SAE), whether the event was', 'expected or unexpected, and the possible relatedness of the event to the study intervention or other study', 'procedures. The Study Clinician will also provide advice for decisions to exclude, refer, or withdraw', 'participants as required. This will include events that are serious, related and unexpected. The study staff', 'will be trained to monitor for and report adverse events and Serious Adverse Events.', 'Definition of Adverse Events and Serious Adverse Events', 'An adverse event (AE) is any untoward or unfavorable medical occurrence in a human subject, whether', 'or not considered study intervention related, which occurs during the conduct of a trial. An adverse event', 'can therefore include high risk of suicide, threat of harm toward self or others, or clinical deterioration', 'as defined by worsened physical or mental health.', 'Suspected adverse reaction is any adverse event for which there is a reasonable possibility that the study', 'intervention caused the adverse event. A reasonable possibility implies that there is evidence that the', 'study intervention caused the event.', 'Adverse reaction is any adverse event caused by the study intervention.', 'An adverse event, suspected adverse reaction, or adverse reaction is considered \"serious\" (i.e., a', 'serious adverse event, serious suspected adverse reaction or serious adverse reaction) if, in the view of', 'either the study medical clinician or sponsor, it:', '1)', 'Results in death: A death occurring during the study or which comes to the attention of the', 'study staff during the protocol-defined follow-up period, whether or not considered caused by', 'the study intervention, must be reported.', '2)', 'Is life-threatening: Life-threatening means that the study participant was, in the opinion of the', 'medical clinician or sponsor, at immediate risk of death from the reaction as it occurred and', 'required immediate intervention. Suicide attempts will be automatically classified as an SAE,', 'given that they are life-threating.', '3) Requires inpatient hospitalization or prolongation of existing hospitalization.', '4) Results in persistent or significant incapacity or substantial disruption of the ability to conduct', 'normal life functions.', '5) Is a congenital abnormality or birth defect.', '6)', 'Important medical event that may not result in one of the above outcomes, but may jeopardize', 'the health of the study participant or require medical or surgical intervention to prevent one of', 'the outcomes listed in the above definition of serious event. This may include threat of harm', 'toward self or others.', 'Definition of Expectedness', '56']\n\n###\n\n", "completion": "END"}